List of Excipients in Branded Drug CYSTADANE

Cystadane Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Cystadane is an oral powder containing betaine anhydrous for the treatment of homocystinuria. Its current commercial formulation is unusually simple: FDA labeling identifies betaine anhydrous as the active ingredient and does not list conventional inactive ingredients.[1] The main commercial opportunity is therefore not an incremental reformulation of an excipient-rich product. It is the development of patient-friendly presentations that improve moisture protection, dosing accuracy, portability, palatability, and pediatric adherence while preserving betaine exposure and regulatory substitutability.

The strongest opportunities are unit-dose sachets, pediatric dosing systems, moisture-resistant packaging, and potentially taste-masked dispersible or ready-to-use presentations. Any reformulation must account for betaine's high dose burden, hygroscopicity, frequent administration, and use in infants and children.

What is Cystadane and how is it formulated?

Cystadane contains betaine anhydrous, also known as trimethylglycine. It is approved for adjunctive treatment of homocystinuria caused by deficiencies of cystathionine beta-synthase, 5,10-methylenetetrahydrofolate reductase, and cobalamin cofactor metabolism.[1]

Cystadane formulation and dosage facts

Attribute	Cystadane profile
Active ingredient	Betaine anhydrous
Dosage form	Oral powder
Administration	Dissolved in water, juice, milk, or formula before administration
FDA dosage strengths	No tablet or capsule strength; dosing is measured by mass
Standard container	180 g bottle with measuring scoop
Dose measurement	One level scoop is approximately 1 g
Typical starting dose	100 mg/kg/day, divided into two daily doses
Adult dose	Commonly 3 g twice daily, titrated to biochemical response
Pediatric use	Includes infants and children
Storage	Tightly closed container at controlled room temperature
Labeled excipients	None identified in the FDA prescribing information

The formulation's low excipient content reduces chemical interaction risk and simplifies manufacturing. It also creates practical weaknesses. Patients and caregivers must open a bottle, measure a powder, and disperse it before administration. Dose sizes can be large, particularly in adults. The formulation has limited portability and provides little control over taste or mouthfeel.

What excipients are used in Cystadane?

Cystadane's FDA prescribing information does not identify conventional inactive ingredients. The product is therefore best characterized as a near-neat or neat betaine anhydrous powder rather than a conventional granulated oral powder containing fillers, binders, sweeteners, or flavoring agents.[1]

This has several consequences for product development:

1. An excipient-based improvement would create a materially different formulation.
2. The added excipient could affect dissolution, dose uniformity, hygroscopicity, stability, or bioavailability.
3. The absence of excipients provides a straightforward baseline for comparative pharmaceutical development.
4. A new product could seek differentiation through presentation and administration rather than through a new pharmacologic mechanism.

What excipients could be considered for a reformulated betaine product?

Potential excipient classes include:

Formulation objective	Candidate excipient strategy	Principal risk
Taste masking	Sucralose, acesulfame potassium, polyols, flavors, ion-exchange resins, coated particles	High dose volume and possible impact on dissolution
Powder flow	Colloidal silicon dioxide, maltodextrin, mannitol, microcrystalline cellulose	Dose dilution and segregation during handling
Moisture control	Minimal hygroscopic carrier, desiccant, high-barrier laminate, moisture scavenger	Water uptake, caking, assay drift
Pediatric dispersion	Mannitol, sucrose, xylitol, suspending agents	Sedimentation, dose nonuniformity, microbial risk if liquid
Granulation	Povidone, hydroxypropyl cellulose, starch derivatives	Slower dissolution and process complexity
Ready-to-use liquid	Purified water, buffer, sweetener, preservative or aseptic packaging	Chemical stability and microbial control
Oral disintegration	Crospovidone, croscarmellose sodium, low-substitution hydroxypropyl cellulose	Large dose mass makes tablets impractical

Excipients with strong commercial value are not necessarily the best technical choice. Betaine is administered in gram quantities, so a small excipient percentage can produce a substantial absolute amount of additional material. A flavor system that is acceptable for a 100 mg dose may be inadequate for a 3 g dose.

Why is moisture control central to the Cystadane excipient strategy?

Betaine anhydrous is a hygroscopic crystalline material. Moisture uptake can cause clumping, loss of flow, inaccurate scooping, and packaging instability. The existing tightly closed bottle reflects this risk.[1]

A reformulation strategy should prioritize moisture management before taste masking. Relevant approaches include:

• High-barrier foil laminate sachets.
• Unit-dose stick packs with low water-vapor transmission rates.
• Induction-sealed bottles with desiccant systems.
• Desiccant-integrated closures.
• Granules engineered to reduce surface moisture uptake.
• In-process water-activity controls.
• Packaging that limits repeated exposure to ambient humidity.

A unit-dose package could provide a stronger commercial proposition than a new excipient blend. It would reduce repeated container opening, improve dose accuracy, support travel, and simplify pharmacy dispensing. The principal tradeoff is higher packaging cost and the need to validate dose uniformity across a large mass of powder.

What formulations are protected by Cystadane?

Public FDA labeling does not identify an active formulation patent or a proprietary excipient system for Cystadane.[1] The commercial formulation is an oral powder based on betaine anhydrous, and the label does not establish protection for a particular sweetener, granulation process, taste-masking system, or delivery device.

Formulation patent opportunities

A follow-on sponsor could seek patent protection for:

• Moisture-stable betaine granules.
• A specific particle-size distribution that improves dispersion.
• A taste-masked betaine powder.
• A unit-dose sachet with defined moisture transmission limits.
• A pediatric liquid or semi-solid formulation with a defined stability period.
• A dosing device calibrated for gram-level betaine administration.
• A combination package containing betaine and a companion vitamin regimen.
• A formulation that maintains dissolution or dose uniformity after defined humidity exposure.

Patent strength would depend on measurable technical parameters rather than broad claims to betaine administration. Useful claim limitations could include water activity, residual moisture, particle-size distribution, dissolution time, assay uniformity, stability after accelerated humidity exposure, and sensory performance.

A patent directed only to adding a common sweetener would likely face substantial obviousness risk. A stronger position would connect the excipient system to an unexpected result, such as improved stability without delayed dissolution, clinically meaningful taste improvement at a high drug load, or improved dose recovery from the package.

When does Cystadane lose exclusivity?

Cystadane's principal regulatory exclusivity was orphan-drug exclusivity, not long-term patent exclusivity. FDA approved Cystadane in 1996 for treatment of homocystinuria, and the product received orphan-drug designation for a rare metabolic disease.[1,2]

Exclusivity category	Cystadane status
FDA approval	1996
Orphan-drug exclusivity	Six years from approval under the Orphan Drug Act
New chemical entity exclusivity	Not the principal historical protection
Pediatric exclusivity	No current commercial relevance to the original approval period
Patent exclusivity	No current label-based formulation protection established
Biosimilar exclusivity	Not applicable
Current market position	Legacy orphan small-molecule product

The six-year orphan period expired years ago. The commercial barrier now rests primarily on physician familiarity, rare-disease diagnosis, reimbursement, supply reliability, manufacturing controls, and the limited size of the patient population.

What is the Orange Book status of Cystadane?

Cystadane is an FDA-approved small-molecule drug, not a biologic. Its relevant abbreviated pathway would be an ANDA for a therapeutically equivalent product if a suitable reference-product and pharmaceutical-equivalence framework is available. A materially different delivery system could require a 505(b)(2) application rather than a conventional ANDA.[3]

The Orange Book analysis should distinguish three questions:

1. Whether Cystadane is listed as an approved reference product.
2. Whether FDA lists unexpired patents for the product.
3. Whether FDA lists exclusivity that would block approval of an ANDA or 505(b)(2) application.

The historical orphan exclusivity period does not permanently block generic development. Any current barrier would more likely arise from product-specific regulatory requirements, manufacturing validation, supply constraints, or a newly patented reformulation.

Are Paragraph IV challenges likely for Cystadane?

A Paragraph IV challenge could be commercially relevant if an applicant seeks approval of a therapeutically equivalent betaine anhydrous powder and the reference listing contains an unexpired patent. Paragraph IV certification is not inherently required simply because Cystadane is an orphan product. It depends on the patents listed for the relevant reference drug.[3]

Generic entry scenarios

Scenario	Likely pathway	Commercial effect
Same active ingredient and comparable oral powder	ANDA, subject to FDA requirements	Price pressure and possible pharmacy substitution
Same active ingredient with different excipients	ANDA if pharmaceutical equivalence and suitability are established	Moderate differentiation, limited protection
Taste-masked or modified presentation	Potential 505(b)(2)	Greater development burden and stronger product differentiation
Ready-to-use liquid	Likely 505(b)(2) unless an applicable generic framework exists	Pediatric convenience and possible premium pricing
Device-assisted dosing system	505(b)(2) or combination-product review issues	Higher regulatory and engineering complexity
Compounded betaine	State and federal compounding rules	Localized competition, variable quality and availability

A generic powder would face a relatively simple active-ingredient profile but still need to demonstrate identity, strength, quality, purity, stability, and appropriate performance. The absence of listed excipients in the reference product can complicate an ANDA strategy because the proposed product may need to show that its excipients do not alter performance or safety.

What pediatric excipient opportunities exist for Cystadane?

Pediatric administration is the clearest product-development opportunity. Cystadane is used in infants and children, but its current presentation requires caregiver measurement and dispersion. A pediatric formulation could improve administration without changing the therapeutic ingredient.

Highest-value pediatric concepts

Unit-dose oral powder

A 1 g or 3 g sachet could reduce weighing and scooping errors. It would also improve portability and limit moisture exposure. Multiple sachet sizes could support weight-based dosing, although a wide range of sachet strengths would raise manufacturing and inventory costs.

Taste-masked powder

A taste-masked product could use sweeteners, flavors, coated particles, or a multiparticulate system. The formulation must disperse rapidly in a small volume and avoid excessive sweetness or osmotic load, particularly in infants.

Oral granules

Granules may improve flow, dose recovery, and dispersion. They may also permit better incorporation of flavoring agents. The main development issue is ensuring that granulation does not slow dissolution or cause segregation of betaine from the excipient fraction.

Ready-to-use liquid

A liquid could remove the preparation step for caregivers. It would introduce chemical and microbiological stability requirements, container-closure validation, preservative tolerability, and potentially shorter shelf life after opening. A dry-to-reconstitute product may offer a better balance between convenience and stability.

Dosing accessory

A calibrated oral dosing device designed for gram-level administration could create a lower-cost improvement. It would not require a new excipient system but could support a differentiated 505(b)(2) product or a lifecycle-management strategy.

How does Cystadane compare with competing betaine products?

Cystadane competes with three broad categories: approved betaine products, compounded betaine, and nonprescription betaine supplements. These products are not automatically interchangeable.

Product category	Regulatory position	Main advantage	Main limitation
Cystadane	FDA-approved prescription drug	Established rare-disease labeling and clinical use	Bottle-based powder and high dose burden
Generic betaine anhydrous	Potential ANDA product	Lower price and substitution potential	Requires approved reference and commercial scale
Compounded betaine	Pharmacy-specific preparation	Custom strength or dosage form	Variable availability, quality, and reimbursement
Betaine HCl supplement	Dietary supplement	Consumer access	Not an established substitute for betaine anhydrous in homocystinuria
Reformulated betaine product	Potential 505(b)(2)	Convenience and differentiation	New clinical, CMC, and regulatory costs

Betaine HCl should not be treated as a direct formulation substitute for betaine anhydrous. The salt form, intended use, quality standards, labeling, and regulatory status differ.

Which companies are challenging Cystadane?

Cystadane does not face the competitive profile of a high-volume primary-care drug. The likely challengers are specialty-generic manufacturers, compounding pharmacies, and rare-disease companies capable of supporting a small patient population.

Potential competitive strategies include:

• A lower-cost oral powder.
• A private-label or regional generic.
• A pediatric sachet.
• A ready-to-use formulation.
• A pharmacy-compounded product with customized dosing.
• A broader metabolic-disease product bundled with nutritional support.

The commercial market is constrained by low patient numbers, specialist prescribing, diagnosis complexity, and reimbursement management. A follow-on product must capture value through adherence, packaging, supply reliability, or price rather than through mass-market promotion.

What revenue exposure does the Cystadane patent estate create?

Cystadane's revenue exposure is more vulnerable to generic entry than to biosimilar competition because betaine anhydrous is a small molecule. There is no biosimilar pathway relevant to the product. The principal erosion risk is a lower-priced oral powder that achieves pharmacy or payer acceptance.

The risk profile is gradual rather than necessarily immediate:

• One generic entrant could pressure net pricing without causing full substitution.
• Multiple ANDA entrants could accelerate price erosion.
• A differentiated pediatric product could protect premium pricing even after generic entry.
• A shortage or quality failure among competitors could preserve branded demand.
• Reimbursement restrictions could favor the lowest-cost approved product.

A protected convenience formulation could extend commercial life without relying on the original orphan exclusivity period. Its value would depend on whether payers recognize a clinical or adherence benefit and whether the sponsor can obtain meaningful substitution resistance.

What manufacturing and intellectual-property barriers affect betaine products?

The active ingredient is not expected to present the manufacturing complexity of a biologic or sterile injectable. The more meaningful barriers are:

• Control of moisture uptake.
• Consistent particle size and flow.
• Uniform filling of gram-level doses.
• Packaging performance under high humidity.
• Stability of flavored or liquid products.
• Avoidance of excipient segregation.
• Reliable supply of pharmaceutical-grade betaine anhydrous.
• Validation of cleaning and cross-contamination controls.
• Scalable production for a low-volume orphan market.

A formulation patent supported by robust CMC data could be commercially more valuable than a broad method-of-use patent, because the original therapeutic indication is well established and method claims may face validity and freedom-to-operate challenges.

Key Takeaways

• Cystadane is a betaine anhydrous oral powder for homocystinuria.
• FDA labeling identifies no conventional inactive ingredients.
• The leading opportunity is a moisture-protected, unit-dose, pediatric-friendly presentation.
• Taste masking is technically attractive but difficult because doses are measured in grams.
• A dry granule, sachet, or dry-to-reconstitute product is likely more practical than a liquid.
• Orphan-drug exclusivity expired long ago; current protection is not based on the original orphan period.
• Biosimilar risk is irrelevant because Cystadane is a small molecule.
• Generic competition would likely proceed through an ANDA if pharmaceutical equivalence is feasible.
• A materially different liquid, taste-masked, or device-assisted product could require a 505(b)(2) strategy.
• The strongest new patent claims would focus on moisture stability, dose uniformity, packaging, sensory performance, and pediatric administration.
• Commercial value will depend on adherence, reimbursement, supply reliability, and manufacturing economics more than on broad exclusivity.

FAQs

Can betaine anhydrous be formulated as a tablet?

Technically, but the high gram-level dose makes tablets commercially unattractive for many patients. A powder, granule, sachet, or liquid is more practical.

Is Cystadane interchangeable with betaine HCl?

No. Betaine anhydrous and betaine hydrochloride are different salt forms with different regulatory and pharmaceutical profiles. They should not be treated as automatically interchangeable.

Would a flavored Cystadane powder require a new FDA application?

A formulation with different excipients may qualify for an ANDA if it meets applicable pharmaceutical-equivalence requirements. A materially different presentation or clinical use could require a 505(b)(2) application.

Can packaging alone create patent protection for a betaine product?

Yes, but a packaging claim must be technically specific and non-obvious. Moisture-barrier performance, stability results, dose recovery, and interaction with the powder would strengthen the position.

What is the most commercially attractive Cystadane lifecycle product?

A unit-dose, moisture-resistant pediatric sachet or dry-to-reconstitute formulation is the strongest near-term concept. It addresses dosing, portability, caregiver burden, and product stability without the full complexity of a ready-to-use liquid.

References

1. U.S. Food and Drug Administration. (2023). Cystadane (betaine anhydrous) prescribing information. Recordati Rare Diseases Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (n.d.). Orphan drug designations and approvals database: Cystadane. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. European Medicines Agency. (n.d.). Cystadane: European public assessment report and product information. https://www.ema.europa.eu/en/medicines/human/EPAR/cystadane

5. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs

6. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda/505b2-applications